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Abstract
Augmenting/reducing of the evoked potential has been
shown to be related to sensation seeking (SS) and spe-
cific clinical disorders. Buchsbaum demonstrated that
patients with bipolar affective disorders (BAD) tend to be
augmenters, as is the case with sensation seekers, and
patients with unipolar affective disorders (UPD) tend to
be reducers. In addition, he reported that prophylactic
medication reduced the tendency to augment in bipolar
patients. However, evidence for these relations is re-
stricted to a few studies. This study explores whether
Buchsbaum’s initial findings can be found in a naturalis-
tic clinical setting. Acoustic evoked potentials were re-
corded for six levels of intensity (59, 71, 79, 88, 92, 96 dB
SPL) from 24 healthy adults, 21 unipolar depressed
patients, and 21 patients with BAD. Participants also
completed personality questionnaires, especially the
Sensation Seeking Scales Form V. Results revealed a
positive correlation between SS and augmenting/reduc-
ing in healthy controls, thereby replicating earlier find-
ings. Bipolar depressed patients showed larger P1/N1
slopes than healthy controls, when medication was sta-
tistically controlled. Unipolar depressed patients showed
smaller P2 slopes, but only when medication was not
controlled. Implications of these results for further re-
search on augmenting/reducing and affective disorders
and their relationship to SS are discussed.
Copyright © 2000 S. Karger AG, Basel
Introduction
A number of findings suggest a positive relation be-
tween sensation seeking (SS) and the augmenting disposi-
tion of the evoked potential (EP) of the EEG [1]. When
stimulus intensity increases, sensation seekers respond
with a marked increase in the P1/N1 or N1/P2 compo-
nent of the EP. This change is also referred to as augment-
ing disposition or ‘high-level intensity dependence’. Since
Zuckerman’s [1] review, this finding has been replicated
several times [2, 3]. In a recent study, we could also con-
firm the correlation between SS and augmenting [4].
However, some of the inconsistencies in the earlier find-
ings still require clarification. Methodological problems
concern the lack of comparability of various EP parame-
ters that were used [5].
There are indications that particularities of the intensi-
ty dependence also appear in certain psychological disor-
ders, for instance in alcoholism and affective disorders [6,
7]. Following the basic work by Buchsbaum et al. [6], sev-
eral studies found that patients with bipolar affective dis-
Augmenting/Reducing in
Affective Disorders
Neuropsychobiology 2000;41:24–30 25
orders (BAD) show a pronounced augmenting disposition
in comparison to healthy controls. Another finding is that
responders to antidepressant or prophylactic medication
are augmenters, whereas nonresponders tend to be reduc-
ers [7, 8]. With regard to unipolar depression (UPD),
Buchsbaum’s findings suggest that these patients exhibit a
significantly lower intensity dependence than did BAD
patients and healthy controls, thereby showing them-
selves to be reducers [9].
Thus far, several findings suggest that sensation seekers
(SS) and BAD share psychophysiological characteristics,
and SS and UPD patients might differ with regard to aug-
menting/reducing. This relationship could turn out to be
mutually indicative of the SS trait and affective disorders
if further findings support the assumption that a high level
of intensity dependence in EP can be taken as an indicator
of low central serotonergic neurotransmission, particu-
larly in the primary auditory cortex [7]. Peculiarities of
central serotonergic neurotransmission are assumed to be
of importance for both SS and affective disorders [7, 10].
In addition, the question arises as to whether BAD and
SS are also associated behaviorally or psychometrically,
and in particular whether SS might be a vulnerability fac-
tor for the development of a bipolar disorder. The psycho-
physiological findings described thus far support this
assumption and correspond well with initial psychometric
findings on the relation between SS and affective disor-
ders. Using the SS Scale Form V (SSS-V) [11], Zuckerman
and Neeb [12] were able to distinguish between controls
and patients with a reported history of bipolar depression.
Cronin and Zuckerman [13] showed that inpatients with
bipolar depression had significantly higher SS scores (sub-
scales disinhibition and boredom susceptibility) than con-
trols, though half of the patients were depressed at the
time of the study.
Little is known about the effects of antidepressant and
prophylactic medication with serotonergic relevance on
the augmenting/reducing characteristic of BAD and
UPD. The study by Buchsbaum et al. [6] revealed a signif-
icant decrease in the intensity dependence of BAD under
lithium (‘flattening effect’). Some studies found the same
effect on the intensity dependence for different patient
groups when tricyclic antidepressants and selective sero-
tonin reuptake inhibitors (SSRI) were used [14, 15, sum-
marized in 7]. Overall, it has not been clarified yet wheth-
er the flattening effect is stable or only transient during
the first time of medication, since appropriate studies
with retests over a respective period are not available.
Thus, the question arises whether the stronger intensity
dependence of BAD patients compared to healthy con-
trols under antidepressant or prophylactic medication
really changes in favor of a flattening effect, and whether
the intensity dependence of both groups is similar under
these conditions.
The study by Buchsbaum et al. [6] does not give evi-
dence of changes on the intensity dependence of unipolar
depressed patients while treated with lithium. So far,
studies on the effect of antidepressant medication with
UPD patients have been mainly restricted to clinical
responsiveness studies [8, 16].
All in all, the actual findings concerning the intensity
dependence of antidepressant or prophylactically medi-
cated BAD and UPD patients in comparison to healthy
controls do not offer sufficient information yet. The
present study investigates the intensity dependence of SS
in healthy individuals. In addition, the aim of the study
was to investigate differences in the intensity dependence
between both affective-disordered groups (BAD, UPD)
and in comparison to healthy individuals. At the psycho-
metric level, it is attempted to replicate the findings of
higher SS scores for BAD and lower SS scores for UPD
when compared to controls.
Methods
Participants
Inpatients with diagnoses of affective disorders were recruited
from the State Mental Hospital Arnsdorf, Germany. Patients’ partic-
ipation did not interfere with their therapeutic treatment. Hospital
staff and interested volunteers were recruited as controls (n = 24; age:
mean = 47, SD = 11; 16 females) and screened for current or past
history of psychiatric illness and substance abuse. Written informed
consent was obtained from all participants.
A structured clinical interview [17] was taken by a trained grad-
uate student, and consensus diagnosis was established together with
an experienced psychiatrist (H.H.). Patients with ambiguous diag-
noses (n = 17) were not included in the analysis. Furthermore,
patients were excluded if they had a past history of organic brain
disorder or substance abuse (n = 5). We obtained EEG retest data
from 27 of the final sample of 42 patients.
According to the International Classification of Diseases [18], 21
patients of the final sample were diagnosed as suffering from UPD (age:
mean = 47, SD = 11; 12 females); of these, 20 patients were classified as
having a depressive episode (F32), and 1 patient as having a recurrent
depressive disorder (F33). The second clinical group consisted of 21
patients with a diagnosis of BAD, who were in different episodes at the
recording time (BAD; F31; age: mean = 43, SD = 12; 8 females). Seven
of the 21 BAD patients had psychotic symptoms, whereas none of the
UPD patients had psychotic symptoms during the time period of the
study. There were no significant differences in age and gender distribu-
tions between BAD, UPD and the control group.
Medication status for all patients was monitored over the interval
of the study. The majority of the UPD patients received antidepres-
sant medication (13 tricyclic antidepressants, 3 SSRI). Two patients
Controls (n = 24)
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received prophylactic medication (lithium), 2 neuroleptic medica-
tion. One patient received anxiolytic medication only, whereas 12
patients received anxiolytic comedication (benzodiazepines). One
UPD patient was unmedicated.
The BAD patients received prophylactic (9 lithium, 5 carbamaze-
pine) or antidepressant medication (3 tricyclic antidepressants, 3
SSRI). Two of them received both antidepressant and prophylactic
medication and 12 anxiolytic or neuroleptic medication as comedi-
cation.
Participants were requested to fill in self-report personality ques-
tionnaires. Special interest was focused on the SSS-V [11] which con-
sists of the four subscales thrill and adventure seeking (TAS), disinhi-
biton (DIS), experience seeking (ES), and boredom susceptibility
(BS).
Data Collection and Quantification
In order to check the stability of the EEG measurements, a retest
was scheduled 2–4 weeks after the initial recording session. Separate
diagnostic sessions, including the assessment of personality dimen-
sions and clinical state, were scheduled within a few days of the EEG
recording sessions. All recordings were scheduled at fixed times and
intervals in the morning.
After audiometric screening of participants, EEG data were
recorded from 19 standard scalp sites (10–20 system) using a fore-
head ground and linked earlobes as reference, while participants sat
in a comfortable arm chair with their eyes open. EEG data were band
pass filtered (0.1–30 Hz) and continuously digitized at 256 sam-
ples/s. To facilitate artifact rejection, the vertical electro-oculogram
was recorded from additional electrodes placed above and below the
right eye. After a recording of 8 min of resting EEG, the acoustic
augmenting/reducing paradigm [19] was administered (13 min time
duration). For a more accurate calculation of the intensity depen-
dence, six different intensity levels were used (59, 71, 79, 88, 92,
96 dB SPL). Stimuli were presented binaurally via headphones in a
pseudorandomized order. Each 1,000-Hz stimulus lasted 30 ms
(10 ms each of rise and fall time), the interstimulus interval varied
between 1,600 and 2,100 ms.
EEG data were epoched off-line from 100 ms before to 400 ms
after stimulus onset. Following baseline correction of the prestimulus
interval to 0 ÌV, epochs with artifacts were excluded automatically if
the EEG signal exceeded B50 ÌV prestimulus or B65 ÌV poststimu-
lus. Long-latency acoustic EP (AEP) were obtained by averaging the
remaining epochs for each stimulus intensity separately (minimum
sweep number 20 epochs). Peak amplitudes were determined for the
P1 as the most positive peak within the period of 25–80 ms, for the
N1 as the most negative peak within 55–135 ms, and for P2 as the
most positive peak within 110–260 ms. Additional peak-to-peak val-
ues were calculated for P1/N1 and N1/P2.
Statistical Analysis
Similar to previous studies, the slopes of the linear regression line
(least-squares technique) for the individual P1, N1, P2, P1/N1 and
N1/P2 amplitudes were calculated across the six stimulus intensities.
However, because the use of regression slopes for the amplitude stim-
ulus intensity function (ASF) has been criticized for their low coeffi-
cients of determination in individual data [20], a nonlinear computa-
tion was also performed [2]. The medians of all possible slopes
between each two amplitudes for the six stimulus intensities (median
slopes) were calculated. All parameters were calculated for C3, Cz
and C4 scalp locations [1].
Table 1. Retest reliabilities of the augmenting/reducing parameters
in controls and patients for ASF slopes and median slopes at three
central scalp sites, separately
Parameters ASF slopes
C3 Cz C4
Median slopes
C3 Cz C4
P1 0.18 0.02 0.14 0.04 –0.08 –0.08
N1 0.38 0.07 0.06 0.08 –0.27 –0.01
P2 0.61 0.77 0.67 0.47 0.65 0.50
P1/N1 0.19 0.30 0.31 0.27 0.17 0.50
N1/P2 0.77 0.71 0.59 0.79 0.80 0.64
Patients (n = 28)
P1 0.20 0.25 0.43 0.24 0.34 0.29
N1 0.53 0.58 0.21 0.53 0.41 0.28
P2 0.41 0.61 0.47 0.23 0.42 0.17
P1/N1 0.22 0.34 0.17 0.41 0.43 0.43
N1/P2 0.17 0.38 0.18 0.03 0.22 0.11
Pearson correlations 10.40 are in italics.
Preliminary analyses addressed the retest reliability of the differ-
ent computations of augmenting/reducing to evaluate effects of elec-
trode site, AEP components, and the method of parametrization for
patients and healthy controls separately. A second recording session
was available from 14 BAD, 14 UPD and 24 control participants.
Additional correlational analyses focused on the relationship of the
augmenting/reducing tendency with the SS trait for healthy partici-
pants only.
To examine the group differences in augmenting/reducing, data
from the first recording session were submitted to a 2 ! 3 repeated-
measures analysis of variance (ANOVA), including position (C3, Cz,
C4) and group. Since we assumed different effects comparing UPD,
BAD and controls, the group differences were tested separately.
Additional analyses included session as a repeated-measures factor
for those participants where a retest was available. Comparisons for
all pairs of groups (UPD vs. controls, BAD vs. controls, UPD vs.
BAD) are reported for ASF slopes only, because analyses for median
slopes revealed similar results.
To be sure that no group effects are interpreted that may be relat-
ed to the effects of antidepressants, medication effects were con-
trolled by means of covariates. The applied medications were coded
as yes (1) or no (0). However, the influence of the covariates is not
independent of the frequency of the medication applied. The total
number of participants receiving partially similar medication is dif-
ferent for the UPD and BAD groups. Therefore, it is important to
control for medication, in order to control for effects due to different
frequencies of medication in the groups. The covariates represent the
direct influence of a medication on augmenting/reducing together
with the frequency of the respective medication and therefore have to
be interpreted with caution.
Differences in SS between UPD, BAD and controls were calcu-
lated by means of t tests, for the SSS-V total scale and the four sub-
scales.
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Fig. 1. Grand average AEP for UPD patients (n = 21), patients with BAD (n = 21), and healthy controls (n = 24) for six
different stimulus intensities at recording site Cz. The AEP components P1, N1 and P2 are indicated for BAD
patients at 59 dB SPL.
Results
Figure 1 shows the AEP for the scalp site Cz for UPD
patients (left column), healthy controls (middle column)
and BAD patients (right column). Averages are separately
displayed for each stimulus intensity level from 59 dB
(bottom) up to 96 dB (top). Independent of group, the P1,
N1, and P2 components of the AEP were apparent at each
level of stimulus intensity. Overall, the augmenting ten-
dency was visible in each group, i.e. a pronounced ampli-
tude increase with increasing stimulus intensity.
Reliability of the AEP Parameters (Intensity
Dependence)
The following test-retest reliabilities (temporal stabili-
ty) were computed for the control group (n = 24) and the
patient group (n = 28) separately. The retest reliabilities
for the parameters differed considerably in both patients
and controls (table 1).
For controls, satisfactory retest reliabilities were
achieved for the ASF slopes for P2 and N1/P2, irrespec-
tive of the electrode site. The slopes of the linear regres-
sion line for the P1, N1, and P1/N1 amplitudes were not
P1
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Table 2. Pearson correlations of the ASF slopes with the SSS-V total score in controls (n = 24)
Parameters First recording session
C3 Cz C4
Second recording session
C3 Cz C4
Aggregated across sessions
C3 Cz C4
0.34 0.27 0.29 0.11 0.15 0.26 0.29 0.30 0.37*
N1 0.30 0.30 0.37* 0.12 0.04 0.22 0.24 0.20 0.40*
P2 0.29 0.37* 0.35* 0.45* 0.34* 0.41* 0.41* 0.38* 0.42*
P1/N1 0.01 –0.01 –0.10 –0.04 0.08 –0.01 –0.02 0.04 –0.06
N1/P2 0.07 0.16 0.00 0.27 0.23 0.16 0.18 0.21 0.09
* p ! 0.05, one tailed.
reliable (table 1). When compared to the ASF slopes, the
reliabilities of the median slopes were not consistently dif-
ferent. For patients, the pattern of reliabilities was less
consistent in comparison to healthy participants. Where-
as the N1/P2 slope was not reliable for patients, accepta-
ble values were obtained for the N1 slopes on C3 and Cz,
and for the P2 slopes on all sites. The pattern of retest
reliabilities was different for ASF slopes and median
slopes. However, across both groups, method of parame-
trization did not affect reliabilities consistently.
SS and Intensity Dependence of the AEP for Healthy
Participants
On both measurement sessions, the most obvious rela-
tionships with the SSS-V total score were found for the P2
slopes, the parameters with the highest reliabilities. This
result remained stable when measurements were pooled
across sessions. The SSS-V total score correlated with the
P2 slopes, which were reliable, but it correlated only
inconsistently with the P1 and N1 slopes (table 2). P1 and
N1 slopes were not reliable in healthy participants. For
the N1/P2, only a correlation with the SSS-V subscale
TAS was found (r = 0.36, p ! 0.05, one tailed) on C3 in the
second recording session. Pooled across sessions, the
slopes of the P1 and N1 on C4 showed significant rela-
tions with the SSS-V total score. Since the correlations of
P1 and N1 slopes with SSS-V scores indicated some valid-
ity of these parameters, we included them into further
analyses. The expected positive correlation between SS
and the intensity dependence of the AEP was confirmed
again by the present results.
Clinical Groups and Intensity Dependence
For the first session, a significant main effect was
found for P1/N1 slopes, when controlled for medication,
confirming the assumption of BAD patients having larger
slopes, when compared to controls, F(1, 37) = 5.91, p !
0.05. The same effect remained significant without BAD
patients medicated with neuroleptics, when controlled for
medication, F(1, 30) = 8.50, p ! 0.01. Similarly, a tenden-
cy was found for the P1 slopes when controlled for medi-
cation, F(1, 37) = 3.88, p = 0.056.
For UPD patients compared to healthy controls, a sig-
nificant group effect was found between the P2 slopes of
UPD patients and controls, F(1, 43) = 5.91, p ! 0.05, with
controls having a larger slope. When controlled for medi-
cation, this effect disappeared, F(1, 38) = 1.34, n.s. Calcu-
lated without the UPD patients treated with neuroleptics,
the effect was significant, F(1, 41) = 5.69, p ! 0.05, but
also disappeared when controlled for medication, F(1, 37)
= 0.74, n.s. A tendency was found for groups when N1/P2
slopes of UPD patients were compared to controls. Again,
UPD patients had smaller slopes when compared to
healthy controls, F(1, 43) = 3.68, p = 0.062. This tenden-
cy was not significant when controlled for medication,
F(1, 38) = 0.42, n.s. Without the UPD patients treated
with neuroleptics, there was a similar tendency for the
N1/P2 slopes, F(1, 41) = 3.18, p = 0.082, which disap-
peared when controlled for medication, F(1, 37) = 0.00,
n.s. The effects of the covariates for tricyclic antidepres-
sive drugs and SSRI were mainly responsible for this
shift.
For the first recording session, none of the compari-
sons between BAD patients and UPD patients reached
significance, even when controlled for medication.
In the ANOVAs for patients with two AEP recording
sessions (15 with UPD, 12 with BAD), there was only a
main effect for UPD patients having smaller N1/P2
slopes than controls, F(1, 37) = 5.01, p ! 0.05. A similar
main effect for the P2 slopes occurred, F(1, 37) = 4.90, p !
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0.05. No main effect for recording session nor any group
! session interaction was found. Despite of changes in
the therapeutic medication of several patients, the effects
remained stable across the recording sessions.
Clinical Groups and SS
As expected, BAD patients had significantly higher
SSS-V total scores than UPD patients, t = –2.29, p ! 0.05
(this and the following significances reflect one-tailed
tests). BAD patients scored significantly higher than UPD
patients on the subscales ES, t = –2.30, p ! 0.05, and DIS,
t = –2.89, p ! 0.01. In addition, BAD patients had greater
SSS-V total scores than controls, t = –1.80, p ! 0.05, and
scored higher on the DIS subscale, t = –2.59, p ! 0.05. For
the differences between UPD patients and controls, there
was – again in accordance with the assumptions – a ten-
dency for ES, t = 1.43, p = 0.08, with UPD patients scor-
ing lower.
The confirmed relationship of SS with ASF slopes in
healthy participants, as well as significant group differ-
ences in SS, may have modulated group differences for
ASF slopes. We therefore reanalyzed our data. The corre-
sponding position ! group ! SS ANOVA was based on a
median split of the SSS-V total score of group-specific
medians. These analyses did not reveal any significant
interaction involving SS for either the first or the second
recording session.
Discussion
At the psychophysiological level, we were again able to
replicate the positive correlation between augmenting and
SS [4, 10]. These findings are especially informative since
the study yields data on the reliabilities of the parameters
used. The correlations with SS were again confirmed for
the P2 slopes in healthy participants. This result may be
due to remarkable reliabilities of this parameter. How-
ever, the N1/P2 slopes, which showed comparable relia-
bilities, only correlated with the TAS subscale. For
healthy participants, inconsistent correlations of the N1
and P2 slopes with SS emerged. This goes parallel with
low reliabilities of the N1 and P2 slopes in this study.
In addition, we found the expected steeper ASF slopes
for BAD patients, i.e. augmenting, when controlled for
medication. Without controlling for medication, no ef-
fects reached significance for ASF slopes. Thus, it is possi-
ble that the medication of the BAD patients flattens the
slopes, and therefore eleminates the differences between
BAD patients and controls [6, 7]. When calculated with-
out patients with neuroleptic medication, the results re-
mained similar, so that the flattening effect may not be
due to neuroleptic medication. However, further studies
with more homogeneously medicated patients are neces-
sary in order to assess the influence of different types of
medication on individual differences in ASF slopes.
Our results indicate that UPD patients have smaller
ASF slopes than controls, but this does not hold when
controlled for medication. This means that the medica-
tion of the UPD patients could be responsible for their
smaller ASF slopes. On the other hand, it might be possi-
ble that UPD patients would still have smaller slopes
without medication, as reported by Buchsbaum et al. [6].
The analyses across recording sessions point into this
direction because UPD patients have smaller ASF slopes
than controls even when medication changes. The
changes in medication in UPD patients across recording
sessions had no effect on the ASF slopes since there was
no significant change in the slopes across sessions. This,
furthermore, indicates that the smaller slope of the UPD
patients cannot be totally attributed to the effects of medi-
cation.
Overall, the results must be regarded with caution,
because it was only possible to control medication effects
on the augmenting/reducing disposition by means of sta-
tistical analysis. Even if equal group size for every type of
medication and comedication could be obtained, there
will always be confounding influences left (e.g. type of dis-
ease and medication), which cannot be completely con-
trolled for. However, these limitations are typically given
in naturalistic settings, since it is neither possible nor rec-
ommended to leave patients unmedicated.
At the psychometric level, the differences in SSS-V
scores confirmed our assumption of BAD patients having
higher scores than UPD patients and controls. This is a
further replication of the results of Zuckerman and Neeb
[12], Cronin and Zuckerman [13] and Carton et al. [21].
Some of the results of Carton et al. [21] could only be
replicated with reservations, because there was only a ten-
dency for the difference between UPD patients and con-
trols. However, SS did not modulate group differences in
ASF slopes, as revealed by reanalyses. The group-specific
differences in SS did not account for additional variance
in ASF slopes. This finding suggests that group character-
istics and SS are highly dependent and that they account
for a large amount of common variance in ASF slopes.
Overall, some psychophysiological and psychometric
differences between BAD and UPD patients and controls
could be demonstrated, which were in line with the few
findings on these relations when controlled for medica-
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tion. In addition, when effects of prophylactic or antide-
pressant medication are not statistically controlled, the
relations are also compatible with the reported character-
istics of the intensity dependence of medicated BAD, i.e.
the flattening effect of the slopes when medicated. How-
ever, due to the naturalistic setting of this study, these
results must be taken with caution and can only be seen as
an indication. Future studies, especially with more re-
stricted medication or with pre/postdesigns, are needed
for further clarification of the characteristic intensity
dependence of unmedicated BAD and UPD patients and
the effects of antidepressant and prophylactic medication
on these groups. However, this is not easily accomplished.
Besides, the prognostic value of SS and augmenting/
reducing in the clinical context might be more appro-
priately assessed in a naturalistic setting.
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